ClinicalTrials.gg
CompletedNCT00354484Updated Feb 20, 2018Results posted

Safety and Efficacy of a Hematinic Agent in the Treatment of Postpartum Patients

A Phase 3 interventional study of Ferric Carboxymaltose (FCM) and Ferrous Sulfate tablets in Postpartum Anemia, sponsored by American Regent, Inc.. Completed at 1 site in United States. Open to female participants. Per ClinicalTrials.gov, last updated 2018-02-20.

Sponsored by American Regent, Inc. (part of Daiichi Sankyo) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
291
Allocation
Randomized
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 54 studies testing ferric carboxymaltose in Anemia — 3 open to participants now, 3 under way, none of them phase 3. ferric carboxymaltose · Anemia.

Enrollment
16th of 54
291 · median 156
Started
2006
the only one that year
Phase 3
23 of 54
none open now
Registered
3rd of 54
by date
Lead sponsor
11 of 54
American Regent, Inc.

Among the 54 studies testing ferric carboxymaltose in Anemia, this one is the 16th largest by enrollment, is the only one that started in 2006, is one of 23 in phase 3, and was the 3rd registered.

Anemia

1,810 studies on the registry are indexed under Anemia; 215 are open to participants now.

Browse Anemia studies →

Open to participants now

3 of the 54 studies testing ferric carboxymaltose in Anemia are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About ferric carboxymaltose

ferric carboxymaltose: first FDA approval 2013 (INJECTAFER). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 122 Anemia studies recruiting now, 67 (55%) set no upper age limit and 37 (30%) stop at 75 or younger; 34 take children under 18; 23 take healthy volunteers.

This study: female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 54 studies testing ferric carboxymaltose in Anemia, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the efficacy, safety, and tolerability of VIT45 compared to the current standard of care in postpartum patients.

Read the detailed description

This is an open label Phase III randomized active control study of postpartum patients with anemia. Patients will be randomized to either active control or the investigational agent and followed for up to 6 weeks.

03

Conditions studied

  • Postpartum Anemia

Browse trials for

Keywords

  • anemia
  • postpartum
04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Female Subjects able to give consent
  • Post partum patients
  • Baseline \< /= 10 g/dL
  • Agree to practice

Exclusion criteria

Exclusion Criteria:

  • Participation in previous clinical trial of this agent
  • Known reaction to active control
  • Significant vaginal bleeding
  • History of anemia other than iron deficiency anemia
  • Anticipated need for surgery during the study
  • Active severe infection or
  • Known positive antigen of viral antibody
  • Known antibodies
  • Received an investigational drug within 30 days of screening
  • Alcohol abuse within past 6 months
  • Hemochromatosis or other iron storage disorders
  • Significant cardiovascular disease
  • Any laboratory abnormality, medical condition or severe psychiatric disorder which in the opinion of the investigator woud put the subject's disease management at risk or may result in the subject being able to comply with the study requirements
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
291 participants (actual)

Study arms

  • Experimental
    Ferric Carboxymaltose (FCM)

    Up to a maximum cumulative dose of 2,500 mg administered IV based on iron-deficit calculations; the calculated dose was given in divided doses of up to 1,000 mg weekly.

    Drug: Ferric Carboxymaltose (FCM)

  • Active comparator
    Ferrous Sulfate tablets

    325 mg of ferrous sulfate 3 times daily (TID) x 6 weeks.

    Drug: Ferrous Sulfate tablets

Interventions

  • Up to a maximum cumulative dose of 2,500 mg administered IV based on iron-deficit calculations; the calculated dose was given in divided doses of up to 1,000 mg weekly.

  • 325 mg of ferrous sulfate 3 times daily (TID) x 6 weeks.

06

What researchers measure

Primary outcomes

  1. Number of Patients Classified as a 'Clinical Success'. Clinical Success Was Defined as the Number of Subjects With an Increase in Hemoglobin of >12 g/dL

    Time frame: anytime between baseline and end of study or time to intervention

  2. Reported Adverse Events

    Time frame: anytime between baseline and end of study or time to intervention

07

Results

Posted Dec 5, 2013

Participant flow

Hospitals and medical clinics

Participant flow — Overall Study
MilestoneFerric Carboxymaltose (FCM)Ferrous Sulfate Tablets
Started142147
Completed138144
Not completed43

Outcome measures

PrimaryNumber of Patients Classified as a 'Clinical Success'. Clinical Success Was Defined as the Number of Subjects With an Increase in Hemoglobin of >12 g/dL
Time frame:
anytime between baseline and end of study or time to intervention
Reported as:
Number · participants
Number of Patients Classified as a 'Clinical Success'. Clinical Success Was Defined as the Number of Subjects With an Increase in Hemoglobin of >12 g/dL
participantsFerric Carboxymaltose (FCM)Ferrous Sulfate Tablets
Number of Patients Classified as a 'Clinical Success'. Clinical Success Was Defined as the Number of Subjects With an Increase in Hemoglobin of >12 g/dL12798
PrimaryReported Adverse Events
Time frame:
anytime between baseline and end of study or time to intervention

Results for this outcome have not been posted.

Adverse events

Collected over 7 months. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Ferric Carboxymaltose (FCM)—4/142 (2.8%)9/142 (6.3%)
Ferrous Sulfate Tablets—4/147 (2.7%)29/147 (19.7%)
Most frequent serious events
Most frequent serious events
EventFerric Carboxymaltose (FCM)Ferrous Sulfate Tablets
EndometritisInfections and infestations0/1422/147
Pelvic abscessInfections and infestations0/1422/147
Pulmonary edemaRespiratory, thoracic and mediastinal disorders1/1420/147
Mitral valve prolapseCardiac disorders1/1420/147
HemorrhoidsGastrointestinal disorders1/1420/147
Cholecystitis acuteHepatobiliary disorders1/1420/147
PyelonephritisInfections and infestations1/1420/147
Pulmonary embolismRespiratory, thoracic and mediastinal disorders0/1421/147
Most frequent other events
Most frequent other events
EventFerric Carboxymaltose (FCM)Ferrous Sulfate Tablets
ConstipationGastrointestinal disorders2/14218/147
HeadacheNervous system disorders7/14211/147

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)Ferric Carboxymaltose (FCM)Ferrous Sulfate TabletsTotal
<=18 years14721
Between 18 and 65 years128140268
>=65 years000
Age, Continuous
Age, Continuous(years)Ferric Carboxymaltose (FCM)Ferrous Sulfate TabletsTotal
Mean26.43 ± 6.0226.49 ± 5.5526.45 ± 5.86
Sex: Female, Male
Sex: Female, Male(Participants)Ferric Carboxymaltose (FCM)Ferrous Sulfate TabletsTotal
Female142147289
Male000
Region of Enrollment
Region of Enrollment(participants)Ferric Carboxymaltose (FCM)Ferrous Sulfate TabletsTotal
United States142147289
08

Study locations

1 site
  • Luitpold Pharmaceuticals
    Norristown, Pennsylvania 19403, United States
09

References and documents

Publications

  • Van Wyck DB, Martens MG, Seid MH, Baker JB, Mangione A. Intravenous ferric carboxymaltose compared with oral iron in the treatment of postpartum anemia: a randomized controlled trial. Obstet Gynecol. 2007 Aug;110(2 Pt 1):267-78. doi: 10.1097/01.AOG.0000275286.03283.18. Erratum In: Obstet Gynecol. 2008 Apr;111(4):996. PubMed 17666600 ↗
  • Seid MH, Rogers R, Dinh Q. Treating Postpartum Anemia with Intravenous Ferric Carboxymaltose: A Randomized Controlled Study. Southern Medical Association Scientific Assembly 2008.
  • Seid MH, Derman RJ, Baker JB, Banach W, Goldberg C, Rogers R. Ferric carboxymaltose injection in the treatment of postpartum iron deficiency anemia: a randomized controlled clinical trial. Am J Obstet Gynecol. 2008 Oct;199(4):435.e1-7. doi: 10.1016/j.ajog.2008.07.046. PubMed 18928998 ↗
  • Seid MH, Rogers R, Dinh Q. The Safety and Tolerability of Ferric Carboxymaltose in Treating Postpartum Women with Iron Dediciency Anemia. American College of Obstetrics & Gynecology District Meeting 2007.
  • Seid MH, Mangione A, Valaoras TG, Anthony LB, Barish CF. Safety Profile of Ferric Carboxymaltose, a New High Dose Intravenous Iron in Patients with Iron Deficiency Anemia. Society for the Advancement of Blood Managment 6th Annual Meeting 2007.
  • Goodnough LT. Treating Postpartum Anemia with Intravenous Ferric Carboxymaltose: a Randomized Controlled Study. Nordic Conference of Obstetrics & Gynecology 2008.
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of May 2006, a primary completion of Dec 2006 and a completion of Jan 2007. It does not say whether these dates are actual or estimated.

Results were first posted in Dec 2013, 7 years after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 13, 2006
First posted
Jul 20, 2006
Start
May 2006
Primary completionActual
Dec 2006
CompletionActual
Jan 2007
Results first posted
Dec 5, 2013
Last update
Feb 20, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 20, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00354484
Responsible party
Sponsor
First posted
Jul 20, 2006
Start date
May 2006
Primary completion
Dec 2006
Completion
Jan 2007
Results posted
Dec 5, 2013
Last update
Feb 20, 2018

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ferric carboxymaltose

Start the discussion